Corus CAD Product Overview
What is the Corus CAD test?
Corus CAD is the only blood test that can help clinicians quickly and safely assess whether or not their patients' chest discomfort or other symptoms may be due to obstructive coronary artery disease (CAD). The Corus CAD test is a decision-making tool that can help identify patients unlikely to have obstructive CAD* as the cause of the patient's symptoms and help clinicians determine appropriate next steps for patient management.
- Has been clinically validated in two prospective, multicenter studies in the U.S. called PREDICT and COMPASS.1,2 Read the highlights.
- Provides an assessment of your patient's likelihood of obstructive CAD without risks associated with imaging radiation, imaging agents, or contrast solutions
- Integrates age, sex, and gene expression to calculate a score, which has been demonstrated to accurately assess the likelihood of obstructive CAD2
- Is the first sex-specific test for obstructive CAD that accounts for key cardiovascular differences between men and women
- Demonstrated high sensitivity (89%) and high negative predictive value (96%) at a score threshold ≤15 in the COMPASS study population of men and women2
- Can be performed through a quick, routine blood draw conveniently administered right in your office
- Delivers objective, reproducible results within a few days
- Complements and improves the current noninvasive assessment of suspected obstructive CAD
Why do I need the Corus CAD test in my practice?
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. In the U.S. alone, CAD—one of the most common CVDs—accounts for nearly one in six deaths according to the American Heart Association.3 We estimate that approximately three million nondiabetic patients in the U.S. with no prior myocardial infarction or revascularization such as stenting or bypass surgery visit their primary care provider each year complaining of symptoms that may be suggestive of obstructive CAD. Studies have shown that only about 10% of these patients actually have obstructive CAD, while approximately 90% of patients have symptoms that stem from other non-cardiac conditions, such as musculoskeletal disorders, gastrointestinal diseases, and psychosocial illnesses.4,5
Moreover, evidence from the New England Journal of Medicine suggests that current modalities for identifying which patients should undergo elective, invasive coronary angiography to diagnose CAD have limitations and that better methods are needed for patient risk stratification.6
Who is the Corus CAD patient?
The Corus CAD test is intended for use in patients who present with stable symptoms suggestive of obstructive CAD.
Typical symptoms suggestive of CAD may include:
- Chest discomfort, tightness, pain, or pressure
- Shortness of breath
Atypical symptoms suggestive of CAD may include:
- Tightness or pressure in the throat, jaw, shoulder, abdomen, back, or arm
- Squeezing, heaviness, or burning sensation in the upper body
- Abdominal discomfort or fullness
- Indigestion or heartburn
- Dizziness or light-headedness
- Palpitations or awareness of heartbeat
(To be suggestive of obstructive CAD, these symptoms should be concurrent with at least one CAD risk factor.*)
The Corus CAD test is NOT intended for patients who:
- Have a history of obstructive CAD
- Have had a prior myocardial infarction or revascularization procedure
- Are diabetic
- Are currently taking steroids, immunosuppressive agents, or chemotherapeutic agents
*Some examples of CAD risk factors include high cholesterol, hypertension, family history of heart disease, smoking, obesity, and known non-cardiac vascular disease.
For a complete description of the intended use population for the Corus CAD test, please see the Corus CAD Intended Use Statement.
What is gene expression?
Gene expression is the term used to describe gene activity, or production of RNA (ribonucleic acid), in response to environmental factors. Gene expression occurs throughout a person's life in all cells and tissues. Gene expression can change in response to disease and other conditions. Some tests incorporate gene expression to help clinicians assess a patient's disease status. Gene expression reflects what's happening in a patient's body right now.
What does Corus CAD measure?
The Corus CAD algorithm integrates age, sex, and gene expression to calculate a score. Combining the Corus CAD score with other patient information provides clinicians with a more complete picture of their patient's CAD status through the test's clinical validity in identifying patients unlikely to have obstructive CAD.
How do I use Corus CAD?
Corus CAD is a simple blood test that can be easily integrated into any practice setting. The test:
- Is performed through a quick, safe blood draw that can be conveniently administered right in your office
- Provides objective, reproducible results typically within a few days
- Complements your current noninvasive assessment of CAD, while improving your ability to identify patients unlikely to have obstructive CAD1,2
How does CardioDx help me incorporate the Corus CAD test into my practice?
To help you seamlessly integrate the Corus CAD test into your practice, CardioDx provides:
- Product support and training
- Specialized consultations with CardioDx Medical Affairs to assist in patient selection and test result interpretation
- Easy, 24-hour access to your patients' reports and customized charts and tables through a secure, web-based Clinician Access Portal
- A dedicated team of insurance experts available to work with patients, clinicians, and payers who will handle all of the billing for the Corus CAD test. The team can also assist by making patients aware of the CARE Patient Financial Assistance Program.
* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or core-lab computed tomography angiography (CTA) (≥2.0mm).
- Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. Ann Intern Med. 2010;153:425-434.
- Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. Circ Cardiovasc Genet. 2013;6(2):154-162.
- Go SO, Mozaffarian D, Roger VL, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics—2013 Update: A Report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
- Cayley WE Jr. Diagnosing the Cause of Chest Pain. Am Fam Physician. 2005;72(10):2012-2021.
- National Ambulatory Medical Care Survey, 2010.
- Patel MR, Peterson ED, Dai D, et al. Low Diagnostic Yield of Elective Coronary Angiography. N Engl J Med. 2010;362:886–895.